JNJ250404C162500
- 0.01
- -0.16-94.12%
Johnson & Johnson Newsroom
Guggenheim Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Announces Target Price $166
Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study
RFK Jr. to Reinstate 20% of HHS Staff Laid off After DOGE Errors
Wells Fargo Adjusts Price Target on Johnson & Johnson to $170 From $152, Keeps Equalweight Rating
Johnson & Johnson Announces TREMFYA Is The First And Only IL-23 Inhibitor To Reduce Both The Signs And Symptoms And The Progression Of Structural Damage In Adults Living With Active Psoriatic Arthritis
Express News | Johnson & Johnson - Tremfya Shows Less Structural Damage Progression at Week 24
Express News | Johnson & Johnson - Tremfya Safety Profile Consistent With No New Safety Signals
Express News | Johnson & Johnson - Tremfya Phase 3B Study Achieves Primary and Secondary Endpoints
Express News | Tremfya® (Guselkumab) Is the First and Only Il-23 Inhibitor to Significantly Reduce Both the Signs and Symptoms and the Progression of Structural Damage in Adults Living With Active Psoriatic Arthritis
Potatoes, Discount Chains and Drugmakers Offer Havens in Stock-market Bloodbath
Express News | Johnson & Johnson - Court Denies Red River Talc's Prepackaged Bankruptcy Plan - SEC Filing
Johnson & Johnson Options Spot-On: On April 3rd, 109.95K Contracts Were Traded, With 470.86K Open Interest
Research Alert: CFRA Keeps Hold Opinion On Shares Of Johnson & Johnson
Stryker, Boston Scientific Down as New Tariffs Impact Medtech Industry
$JNJ Stock Is up 3% Today. Here's What We See in Our Data.
US stocks are moving differently | The three major indices plummeted, but defensive stocks held strong! Coca-Cola (KO.US) rose over 3%.
Against the backdrop of a global stock market crash, defensive stocks in the U.S. market performed well.
Express News | Shares of Abbvie up 2.5%, Johnson & Johnson up 2.5%, Merck up 1.9%, Amgen up 2.2%
Pharma Stocks up on US Tariff Exemptions but Analyst Flags a $46B Import Cost Risk
Barclays Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $166
Guggenheim Maintains Johnson & Johnson(JNJ.US) With Hold Rating